DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics ...

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

This was the stock's second consecutive day of losses.

According to Benzinga Pro, Quest Diagnostics's peer group average for short interest as a percentage of float is 9.65%, which means the company has less short interest than most of its peers. Did you ...

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

Shares of Quest Diagnostics Inc. DGX slid 2.74% to $159.80 Tuesday, on what proved to be an all-around dismal trading session ...

Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned diagnostics provider posted adjusted earnings per share (EPS ...

Despite a change in ownership, the diverse mix of tenants is expected to remain at this popular Beach Boulevard marketplace.

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $189 from $178 and keeps an Outperform rating on the shares. The firm ...

Detailed price information for Quest Diagnostics Inc (DGX-N) from The Globe and Mail including charting and trades.

"Quest's AD-Detect suite of advanced diagnostics has grown to include a range of validated blood-based biomarkers, giving providers options for personalizing testing for the individual patient ...